[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Second Hospital of Shanxi Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":263},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,79,104,132,154,178,199,221,243],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641827","transcutaneous-electrical-acupoint-stimulation-for-perioperative-sleep-disturbances-in-cancer-patients-100641827",false,"NCT07654075","Transcutaneous Electrical Acupoint Stimulation for Perioperative Sleep Disturbances in Cancer Patients","Clinical Study on Transcutaneous Electrical Acupoint Stimulation (TEAS) for the Prevention and Treatment of Perioperative Sleep Disturbances in Cancer Patients","Inclusion Criteria:\n\n* Patients aged between 18 and 75 years old, regardless of gender.\n* Diagnosed with malignant tumors requiring elective surgery under general anesthesia.\n* ASA physical status I-III.\n* Able to understand and complete study-related questionnaires (PSQI, AIS, NRS, etc.).\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Severe cardiac, hepatic, renal or respiratory dysfunction that affects the implementation of TEAS.\n* History of psychiatric disorders or use of psychotropic drugs.\n* History of drug or alcohol abuse.\n* Presence of infection, skin lesions or contraindications at TEAS acupoints.\n* Preoperative use of strong opioids (e.g., morphine, oxycodone) for more than 1 week.\n* Pregnant or lactating women.\n* Participation in other clinical trials within 3 months prior to enrollment.\n* Inability to cooperate with the study due to cognitive impairment or language barriers.","ALL","18 Years","75 Years",{"count":20,"type":21},176,"ESTIMATED","INTERVENTIONAL",[24],"NA","Postoperative sleep disturbance (POSD) is highly prevalent among cancer patients after tumor resection, affecting 43%-80% of perioperative individuals. Poor sleep aggravates postoperative pain, anxiety and adverse cardiovascular events, hindering postoperative recovery. Conventional hypnotic medicines carry potential risks of drug dependence and respiratory depression.\n\nTranscutaneous Electrical Acupoint Stimulation (TEAS) is a non-invasive physical therapy derived from traditional acupuncture, which delivers low-frequency electrical stimulation on acupoints. Previous small-scale researches suggest TEAS may improve perioperative sleep, but high-quality randomized controlled trial evidence for cancer surgical patients is insufficient.\n\nThis single-center randomized sham-controlled trial aims to verify whether perioperative TEAS at Shenmen (HT7), Neiguan (PC6) and Hegu (LI4) can improve postoperative sleep quality, relieve surgical pain and regulate stress hormone level. A total of 176 eligible patients aged 18-75 years undergoing elective gastrointestinal or gynecologic cancer resection under general anesthesia will be enrolled and randomly divided into 1:1 intervention group and sham control group. The TEAS group receives acupoint electrical stimulation from pre-anesthesia to the end of surgery, while control group uses identical electrodes without actual electrical output. All subjects receive standardized anesthesia and routine postoperative analgesia. Researchers evaluate primary outcomes including PSQI and AIS sleep scales, alongside secondary indicators such as VAS pain score, QoR-15 and serum cortisol at postoperative Day1, Day3, Day7 and postoperative 30-day follow-up.",[27],"Postoperative Sleep Disturbance",[29,30,31,32],"postoperative sleep disturbance","transcutaneous electrical acupoint stimulation","cortisol","Shenmen (HT7), Neiguan (PC6), Hegu (LI4)","NOT_YET_RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-17","ACTUAL",{"date":39,"type":21},"2026-06-13",{"date":41,"type":21},"2026-07-20",{"name":43,"class":44},"Second Hospital of Shanxi Medical University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":78,"locationsCount":45},"100641884","ultrasound-assessment-of-sciatic-nerve-and-inferior-gluteal-artery-in-diabetic-peripheral-neuropathydpn-association-with-a-target-gene-100641884","NCT07595887","Ultrasound Assessment of Sciatic Nerve and Inferior Gluteal Artery in Diabetic Peripheral Neuropathy(DPN): Association With a Target Gene","An Observational Study to Explore the Early Diagnostic Value of Ultrasonographic Sciatic Nerve Cross-Sectional Area and Inferior Gluteal Artery Blood Flow Velocity in Patients With Diabetic Peripheral Neuropathy Stratified by Severity: Integrating Bioinformatics-Based Exploration of Neuropathy Mechanisms and Correlation With a DPN Target Gene","Inclusion Criteria:\n\n* Patients diagnosed with type 2 diabetes mellitus according to the World Health Organization (WHO) diagnostic criteria; Aged between 20 and 75 years; Willing to provide written informed consent; Ability to comply with all study assessments including ultrasound examination, nerve conduction studies, and blood sampling.\n\nExclusion Criteria:\n\n* Peripheral neuropathy caused by non-diabetic conditions, including severe hepatic or renal disease, nutritional deficiencies, connective tissue diseases, or other metabolic or hereditary disorders; Nerve root compression due to cervical spondylosis or lumbar disc herniation; History of chronic alcohol abuse or long-term exposure to toxic substances (e.g., heavy metals) that may cause peripheral nerve damage; History of medication use known to affect peripheral nerve function (e.g., isoniazid, furazolidone)","20 Years",{"count":55,"type":21},120,"OBSERVATIONAL","Diabetic peripheral neuropathy (DPN) is a common and serious complication of diabetes that causes numbness, pain, and weakness, often starting in the feet. Currently, there is no cure, and early diagnosis is difficult with standard tests alone. This observational study aims to find better ways to detect DPN in its early stages.\n\nThe researchers will use high-frequency ultrasound, a painless and non-invasive imaging tool, to measure two things in patients with type 2 diabetes: the cross-sectional area of the sciatic nerve (to look for swelling) and the blood flow velocity in the inferior gluteal artery (a vessel that supplies the nerve).In parallel, a bioinformatics analysis has identified a key target gene, Matrix Metalloproteinase 9(MMP9), which may play a role in nerve damage through a specific signaling pathway. The level of this protein will be measured in the patients' blood.\n\nA total of 120 participants will be grouped by the severity of their nerve damage, assessed by Toronto Clinical Scoring System (TCSS). The study will investigate whether the ultrasound measurements correlate with the clinical scores, nerve conduction studies, and the blood levels of the target protein. The ultimate goal is to combine these ultrasound structure, blood flow function, and molecular markers to build a more accurate tool for the early diagnosis and precise management of DPN, bridging the gap from early warning to mechanism-based care.",[59],"Diabetic Peripheral Neuropathy (DPN)",[61,62,63,64,65,66,67,68,69,70,71],"Diabetic Peripheral Neuropathy","Type 2 Diabetes","High-Frequency Ultrasound","Sciatic Nerve Cross-Sectional Area","Inferior Gluteal Artery Blood Flow","Matrix Metalloproteinase 9 (MMP9)","Nociceptin\u002FOrphanin FQ (N\u002FOFQ)","Toronto Clinical Scoring System (TCSS)","AMPK Signaling Pathway","Early Diagnosis","Observational Study","2026-06-12",{"date":74,"type":37},"2026-06-16",{"date":76,"type":21},"2026-05-20",{"date":41,"type":21},{"name":43,"class":44},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100557342","phase-2-tislelizumab-combined-with-chemotherapy-and-thoracic-radiotherapy-in-es-sclc-100557342","NCT06536868","Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC","Tislelizumab Plus Chemotherapy and Concurrent Thoracic Radiotherapy as First-line Therapy for Extensive-stage Small-Cell Lung Cancer (ES-SCLC): an Multicenter, Single Arm Prospective Trial","Inclusion Criteria:\n\n* Patients aged between 18 to 80 years old (inclusive of 18th and 80th birthdays), male or female, at the time of signing the informed consent form;\n* Confirmed small cell lung cancer of extensive stage by histology or cytology;\n* At least one measurable lesion by imaging studies (according to RECIST 1.1) with a long diameter of ≥10 mm as examined by spiral CT or MRI;\n* Within 3 days prior to treatment, an ECOG score of 0 to 1;\n* No prior antitumor treatment for extensive stage disease (if the patient has previously received chemotherapy and\u002For radiotherapy in the limited stage of SCLC, the treatment intent must have been curative, and there must be at least a 6-month treatment-free interval between the end of chemotherapy, radiotherapy, or chemoradiotherapy and the diagnosis of extensive stage SCLC);\n* Expected life span of ≥3 months;\n* Good function of vital organs;\n* The subject voluntarily joins this study, signs the informed consent form, has good compliance, and cooperates with follow-up.\n\nExclusion Criteria:\n\n* Concurrent severe respiratory diseases: such as pulmonary fibrosis;\n* Presence of psychiatric disorders, hematologic diseases, autoimmune diseases, and severe primary diseases of the heart, brain, liver, or kidneys;\n* Uncontrolled active infections;\n* Known or suspected allergies to the study medication and its excipients;\n* Female patients who are pregnant or breastfeeding, or women of childbearing potential with a positive baseline pregnancy test;\n* Prior use of antitumor treatment targeting the PD-(L)1 pathway.","80 Years",{"count":88,"type":21},40,[90],"PHASE2","This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.",[93],"Extensive-stage Small-cell Lung Cancer","RECRUITING","2026-04-21",{"date":97,"type":37},"2026-04-24",{"date":99,"type":37},"2024-08-01",{"date":101,"type":21},"2026-12-31",{"name":43,"class":44},6,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":45},"100593935","early-phase-1-relationship-between-remimazolam-and-etomidate-in-induction-of-general-anesthesia-100593935","NCT07012902","Relationship Between Remimazolam and Etomidate in Induction of General Anesthesia","The Interaction Between Remimazolam and Etomidate During Induction of General Anesthesia Was Studied by Isoradiometric Analysis","Inclusion Criteria:\n\n1. Both sexes\n2. aged 18-60 yr\n3. ASA physical status I-II\n4. BIM: 18-28kg\u002Fm²\n\nExclusion Criteria:\n\n1. allergic to remimazolam and etomidate\n2. in pregnancy or lactation\n3. serious cardiovascular diseases, long-term alcoholism\n4. used sedative drugs or opioids within 24 hours\n5. severe mental illness and myasthenia gravis -","60 Years",{"count":113,"type":21},125,[115],"EARLY_PHASE1","In modern anesthesia practice, anesthesiologists often need to choose a combination of multiple drugs according to the specific conditions and surgical needs of patients, which can not only achieve more fine anesthesia management, but also improve perioperative safety and patient comfort. In clinical practice, anesthesiologists will use etomidate combined with a small dose of remimazolam for anesthesia induction to obtain more stable hemodynamics, prevent intraoperative awareness, and relieve anxiety.However, what is the best dose ratio of etomidate combined with remimazolam, the current literature does not give clear indicators.",[118,119],"Induction Anesthesia","Drug Interactions",[121,122,123],"Isoradiation analysis","etomidate","remimazolam","2025-06-08",{"date":126,"type":37},"2025-06-10",{"date":128,"type":21},"2025-06-12",{"date":130,"type":21},"2025-07-19",{"name":43,"class":44},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":140,"minAge":53,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":45},"100592327","analysis-of-factors-associated-with-the-occurrence-of-amniotic-fluid-entry-in-patients-undergoing-caesarean-section-100592327","NCT06991985","Analysis of Factors Associated With The Occurrence of Amniotic Fluid Entry in Patients Undergoing Caesarean Section","AOFAWTOOAFEIPU","Inclusion Criteria:\n\n* Approved consent and informed consent of the patient by the Ethics Committee of the Second Hospital of Shanxi Medical University;\n* ASA classification of I-III;\n* Age 20-50 years old;\n* No previous history of psychiatric diseases or psychotropic drugs;\n\nExclusion Criteria:\n\n* Suffer from diseases of the cardiorespiratory system;\n* Those with communication difficulties who were unable to complete the screening questionnaire;",true,"FEMALE","50 Years",{"count":55,"type":21},"To compare serum STN （Neuraminic acid-N-acetylgalactose）antigen concentrations in patients undergoing cesarean section and to study the factors associated with amniotic fluid entry.Compare the serum complement C4 concentration in patients in the amniotic fluid admission group with those in the non-admission group to study whether amniotic fluid admission triggers the body's immune response.To record the patients' blood pressure, heart rate, blood oxygen, and the occurrence of related symptoms and adverse reactions at the time of admission, at the time of blood collection, at the time of discharge from the room, and at the time of the occurrence of haemodynamic changes.",[145],"Amniotic Fluid Embolism","2025-05-19",{"date":148,"type":37},"2025-05-28",{"date":150,"type":21},"2025-05-20",{"date":152,"type":21},"2025-12-31",{"name":43,"class":44},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":140,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100592233","network-pharmacology-was-applied-to-explore-the-mechanism-of-remimazolam-applied-in-general-anesthesia-for-gynecological-surgeries-100592233","NCT06990763","Network Pharmacology Was Applied to Explore the Mechanism of Remimazolam Applied in General Anesthesia for Gynecological Surgeries","Clinical and Molecular Mechanism Study of Remimazolam Regulating the N\u002FOFQ-inflammation-immune Axis to Optimize the Effect of General Anesthesia in Gynecological Surgery","Inclusion Criteria:\n\n1. The patient or their family members sign the informed consent form\n2. Age: 18-64 years old, BMI: 18-30kg\u002Fm2\n3. ASA Grade Ⅰ or Ⅱ\n4. Patients undergoing gynecological surgeries (laparoscopic total hysterectomy, adnexectomy and myomectomy)\n\nExclusion Criteria:\n\n1. People who are allergic to remimazolam or benzodiazepinesThyroid disease\n2. Long-term use of benzodiazepines\n3. Pregnancy or lactation\n4. Have a history of drug abuse or alcoholism\n5. Patients with contraindications for surgery\n6. Patients with hypertension (clinically diagnosed with hypertension) and patients with coronary heart disease (with typical angina pectoris symptoms and excluding aortic valve lesions, with a clear history of old myocardial infarction, with a clear history of acute myocardial infarction, and CAG finding coronary artery stenosis greater than or equal to 70%)\n7. Patients with arrhythmia, heart failure, renal failure, and those who have recently taken cardiovascular active drugs\n8. Endocrine disorders such as hyperthyroidism and pheochromocytoma that may affect the hemodynamic level of the body\n9. Patients with ketoacidosis and lactic acidosis\n10. Abnormal liver function, ALT\\> three times the upper limit of the normal value;\n11. Renal failure (serum creatinine \\>3mg\u002Fdl or creatinine clearance rate \\\u003C30ml\u002Fmin)\n12. Patients who have been using sedatives or antidepressants for a long time, or have a history of alcohol abuse or drug dependence\n13. Asthma or reactive airway diseases\n14. Combined with underlying cognitive function abnormalities\n15. Exclusion criteria for research subjects\n16. Those who were mistakenly included without meeting the inclusion criteria\n17. Those who experienced adverse events such as shock, severe hypotension and severe arrhythmia during the operation","64 Years",{"count":88,"type":21},[24],"To explore the related mechanisms by which remimazolam regulates hemodynamic stability, inflammatory factors and the immune system in patients undergoing general anesthesia for gynecological surgeries.",[166],"Gynecological Disease",[123,168,169],"propofol","gynecological disease","2025-05-17",{"date":172,"type":37},"2025-05-25",{"date":174,"type":21},"2025-06-01",{"date":176,"type":21},"2026-01-01",{"name":43,"class":44},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":139,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100588910","the-mechanism-of-endogenous-nociceptinorphanin-fqnofq-and-1-adrenoceptor-autoantibody-in-promoting-ischemic-arrhythmia-in-rats-100588910","NCT06947551","The Mechanism of Endogenous Nociceptin\u002FOrphanin FQ(N\u002FOFQ) and β1-adrenoceptor Autoantibody in Promoting Ischemic Arrhythmia in Rats","tmoenabaaipiai","Inclusion Criteria:1) Inclusion criteria for patients with diabetes: refer to the diagnostic criteria for type 2 diabetes (T2DM) in the Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes (2017) 2) Inclusion criteria for patients with coronary heart disease: patients with clinically diagnosed coronary heart disease according to the 1979 WHO Diagnostic Criteria for Ischemic Heart Disease, and exclusion criteria include heart failure, tumor, immune disease and diabetes. -\n\nExclusion Criteria:Exclusion criteria for patients with coronary heart disease: including heart failure, tumor, immune disease and diabetes. -","85 Years",{"count":187,"type":21},60,"In the early stage of ischemic arrhythmia, endogenous N\u002FOFQ regulates the expression of β 1-AA, mediates the internalization of β 1-AR by PKC\u002FERK1\u002F2, and thus affects the occurrence of arrhythmia. Further clarify the regulatory mechanism of N\u002FOFQ on β 1-AR internalization and arrhythmia, providing experimental basis for drug development and target exploration of clinical ischemic arrhythmia; To observe the relationship between endogenous N\u002FOFQ and β 1-AA in serum of patients with coronary heart disease and diabetes.",[190],"Acute Myocardial Ischemia","2025-04-25",{"date":193,"type":37},"2025-04-27",{"date":195,"type":21},"2025-05-01",{"date":197,"type":21},"2026-06-01",{"name":43,"class":44},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":139,"sex":16,"minAge":17,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":218,"leadSponsor":220,"locationsCount":45},"100578249","sufentanil-in-patients-with-lower-extremity-fracture-surgery-myocardial-damage-function-study-100578249","NCT06808841","Sufentanil in Patients With Lower Extremity Fracture Surgery Myocardial Damage Function Study","Sufentanil is Paired Via the BMP6\u002FSMAD Pathway Cardiac Injury in Lower Extremity Fracture Surgery Function Study","Sipwlefsmdfs","Inclusion Criteria:\n\n* There were 160 patients aged 18-65 years and older who needed surgery for lower extremity fracture.\n* ASA grades I to III, gender is not limited.\n\nExclusion Criteria:\n\n* Patients with acute myocardial infarction in the last 6 months, those with a history of heart failure, and those with elevated troponin levels before injury.\n* Old fracture\n* Stroke patients\n* Liver cirrhosis, kidney failure\n* Serious systemic infections, alcoholism, drug dependence\n* Pathological fracture\n* Use of glucocorticoids in the past one month\n* Diabetic","65 Years",{"count":209,"type":21},160,[24],"1. To analyze the association of different doses of opioids on myocardial injury\u002Fprotection through BMP-6\u002FSMAD pathway.\n2. To observe the effect of different doses of opioids on the expression of BMP-6 in bone marrow.\n3. To investigate the relationship between different doses of opioids and BMP-6 and perioperative cardiovascular adverse events in patients with lower extremity fracture surgery.",[213],"Myocardial Injury","2025-02-04",{"date":216,"type":37},"2025-02-05",{"date":216,"type":21},{"date":219,"type":21},"2025-05-10",{"name":43,"class":44},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},"100559913","nintedanib-for-the-prevention-of-radiation-pneumonia-in-unresectable-nsclc-100559913","NCT06570317","Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC","Prospective, Multicentre Phase II Clinical Study of Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC","Inclusion Criteria:\n\n* 1\\) Men or women who are over 18 years old (including 18 years old) when signing the informed consent form;\n* 2\\) Non-small cell lung cancer was confirmed by histology and could not be resected, and EGFR\u002FALK driver gene was confirmed negative by gene mutation examination;\n* 3\\) At least one measurable lesion with imaging examination (according to RECIST1.1) is examined by spiral CT or MR, and the length and diameter of the lesion are ≥ 10 mm;\n* 4\\) within 3 days before treatment, the score according to ECOG is 0 \\~ 1;\n* 5\\) Life expectancy ≥3 months;\n* 6)The vital organs function well,\n* 7)The subjects volunteered to join the study and signed the informed consent form, with good compliance and cooperation with the follow-up.\n\nExclusion Criteria:\n\n* 1\\) Complicated with severe respiratory diseases: pulmonary fibrosis, active tuberculosis, etc.\n* 2)Persons with mental disorder, blood system diseases, autoimmune diseases and serious primary diseases of heart, brain, liver and kidney;\n* 3\\) Hemorrhagic events that require blood transfusion, invasive intervention or hospitalization occur within 3 months before the first administration, or there are bleeding symptoms and need intervention treatment (such as hemoptysis, hematuria and bloody stool), or high-risk factors with bleeding risk (such as tumor surrounding or invading important blood vessels, obvious necrosis or cavity around tumor, esophageal varices, etc.);\n* 4\\) Thrombosis or embolic diseases, abnormal blood coagulation function and bleeding tendency;\n* 5\\) Known or suspected to be allergic to the study drug and its auxiliary materials;\n* 6\\) The baseline pregnancy test of pregnant and lactating women or fertile women is positive.\n* 7\\) According to the researcher's judgment, the subjects have other factors that may lead to the forced termination of this study.",{"count":88,"type":21},"This study is aimed at patients with unresectable NSCLC who take nintedanib during sequential radiotherapy to explore the incidence of radiation pneumonitis above grade 2 in the nintedanib combined with radiotherapy mode and observe safety. And will further explore the progression-free survival (PFS) and overall survival (OS) of patients treated with nintedanib in combination with radiotherapy and immunotherapy.\n\nPrimary objective: To evaluate the safety of nintedanib combined with sequential radiotherapy in patients with unresectable NSCLC and the incidence of radiation pneumonitis above grade 2. Secondary objective: To evaluate the changes in lung function, progression-free survival (PFS) and overall survival (OS) in patients with unresectable NSCLC after nintedanib combined with sequential radiotherapy.\n\nPatients need to receive induction therapy, chemotherapy and\u002For immunotherapy for at least one cycle. Then they will receive sequential radiotherapy and nintedanib for 6 months. Finally, they will receive immunotherapy maintenance therapy for 16 cycles.",[231,232,233],"NSCLC","Nintedanib","Radiation Pneumonitis","2024-08-22",{"date":236,"type":37},"2024-08-26",{"date":238,"type":21},"2024-08-24",{"date":240,"type":21},"2026-06-30",{"name":43,"class":44},7,{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":139,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":45},"100552127","relationship-between-serum-nofq-and-acute-myeloid-cell-leukemia-100552127","NCT06469047","Relationship Between Serum N\u002FOFQ and Acute Myeloid Cell Leukemia","RBSNAAMCL","Inclusion Criteria:\n\n* In accordance with adult acute myeloid leukemia (non-acute promyelocytic leukemia)The diagnostic criteria for AML in the Chinese Diagnosis and Treatment Guidelines (2017 edition); ②Leukocyte count ≤ 25×109\u002FL;\n\n  * No treatment has been received in the past 6 months.\n\n    * None of the candidates are related and known this study, and sign the informed consent.\n\nExclusion Criteria:\n\n* Patients who are allergic to the drugs used in this study;\n\n  * People with mental illness or cognitive impairment;\n\n    * Patients with infectious diseases; ④Patients with severe heart, liver, kidney and other organ function lesions; ⑤ Combined with other malignant swelling. The tumor.",{"count":251,"type":21},80,"Patients diagnosed with acute myeloid leukemia in the Second Hospital of Shanxi Medical University were selected and divided into the newly diagnosed group, the relapsed group, the complete remission group as the experimental group, and the healthy physical examination subjects as the control group. The relationship between IL-1β, catecholamine and norkephalin in peripheral blood of the experimental group and the control group was observed. According to the literature, the experimental group was significantly higher than the control group. In the experimental group, the newly diagnosed group was higher than the relapse group, and the relapse group was higher than the complete remission group, and the correlation was positive, and the difference was statistically significant.",[254],"AML","2024-06-16",{"date":257,"type":37},"2024-06-21",{"date":259,"type":21},"2024-06-20",{"date":261,"type":21},"2024-12-31",{"name":43,"class":44},""]